Professional Media briefs

Share this article:
Catherine DeAngelis will step down from her post as JAMA editor-in-chief next June, the journal said, and return to Johns Hopkins. During her 10-year career at the AMA-published medical publication, DeAngelis toughened conflict-of-interest guidelines, worked to require registration of clinical trials as a condition of publication and established the JAMA requirement that industry-sponsored clinical trials must have an independent academic statistician to review all data before a manuscript can be accepted and published. She was also criticized for letting some author conflicts go undisclosed.

A Columbia University study found that in 2007, 25 out of 32 consultants to medical device firms drawing $1 million-plus compensation failed to reveal those conflicts of interest in journal articles published the following year. The authors called for tougher disclosure policies at medical journals.

The FDA's Division of Drug Marketing, Advertising and Communication hit Baxter with a warning letter for a physician brochure for Aralast NP, expressing concern over “your continued violative promotion of your products” and citing two previous letters.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions